Neuron-specific enolase and brain-derived neurotrophic factor levels in umbilical cord blood in full-term newborns with intrauterine growth retardation

Morozova, A. Yu.; Юрьевна, Морозова Антонина; Milyutina, Yu. P.; Павловна, Милютина Юлия; Kovalchuk-Kovalevskaya, Olga V.; Владимировна, Ковальчук-Ковалевская Ольга; Arutjunyan, А. V.; Вартанович, Арутюнян Александр; Evsyukova, I. I.; Ивановна, Евсюкова Инна

doi:10.17816/jowd68129-36

Cited by 7 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These would have also been excluded for other reasons such as not meeting FGR definition (very low birth weight, preterm birth only), not assessing neurodevelopmental outcomes, or that no blood biomarkers were assessed. One study was excluded as it did not include neurodevelopmental assessments (36) and another was excluded as it reported only the presence of brain injury for the FGR cohort (37). Finally, one study was a twin study but was excluded as it did not separate the FGR twins from the normally grown pair for comparison (38).…”

Section: Resultsmentioning

confidence: 99%

“…Small for gestational age (SGA) differs from FGR in that it is solely defined by birthweight <10th percentile (3)(4)(5). We observed, however, that the studies included for full text review that included SGA cohorts either did not have a cohort of NG infants as controls or did not conduct a neurodevelopmental assessment >12 months of age for the NG cohort (31)(32)(33)(34)(35)(36)(37). Therefore, even when broadening the inclusion criteria to include SGA infants, our search of the current literature still only yielded one study that met all inclusion criteria.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The search for blood biomarkers that indicate risk of adverse neurodevelopmental outcomes in fetal growth restriction

Musco,

Beecher,

Chand

et al. 2024

Front. Pediatr.

View full text Add to dashboard Cite

Fetal growth restriction (FGR) impacts 5%–10% of pregnancies and is associated with increased risk of mortality and morbidity. Although adverse neurodevelopmental outcomes are observed in up to 50% of FGR infants, a diagnosis of FGR does not indicate the level of risk for an individual infant and these infants are not routinely followed up to assess neurodevelopmental outcomes. Identifying FGR infants at increased risk of adverse neurodevelopmental outcomes would greatly assist in providing appropriate support and interventions earlier, resulting in improved outcomes. However, current methods to detect brain injury around the time of birth lack the sensitivity required to detect the more subtle alterations associated with FGR. Blood biomarkers have this potential. This systematic review assessed the current literature on blood biomarkers for identifying FGR infants at increased risk of adverse neurodevelopmental outcomes at >12 months after birth. Four databases were searched from inception to 22 February 2024. Articles were assessed for meeting the inclusion criteria by two reviewers. The quality of the included article was assessed using Quality Assessment of Diagnostic Accuracy Studies-2. A summary of findings is presented as insufficient articles were identified for meta-analysis. Excluding duplicates, 1,368 records were screened with only 9 articles considered for full text review. Only one article met all the inclusion criteria. Quality assessment indicated low risk of bias. Both blood biomarkers investigated in this study, neuron specific enolase and S100B, demonstrated inverse relationships with neurodevelopmental assessments at 2 years. Four studies did not meet all the inclusion criteria yet identified promising findings for metabolites and cytokines which are discussed here. These findings support the need for further research and highlight the potential for blood biomarkers to predict adverse outcomes.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=369242, Identifier CRD42022369242.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

The search for blood biomarkers that indicate risk of adverse neurodevelopmental outcomes in fetal growth restriction

Musco,

Beecher,

Chand

et al. 2024

Front. Pediatr.

View full text Add to dashboard Cite

show abstract

Neuroprotective effect of cytoflavin in the treatment of premature newborns with hypoxic-ischemic encephalopathy

Salikhova,

Agzamhodjayeva,

Abdurahmanova

et al. 2024

S.S. Korsakov J. Neuro. Psych.

View full text Add to dashboard Cite

Gestational diabetes mellitus and obesity: effects on offspring

Рожкова

Ремнева

Fadeeva

et al. 2021

Akušerstvo, ginekologiâ i reprodukciâ

View full text Add to dashboard Cite

Aim: to identify the risk factors for gestational diabetes mellitus (GDМ) and predictors of perinatal lesions of central nervous system (CNS) combined with GDМ and maternal obesity.Materials and Methods. А retrospective observational case-control non-combined study was conducted to determine GDМ risk factors and their effect on perinatal pathology in 250 women divided into 2 groups. The main group included 150 pregnant women diagnosed with GDМ, the control group – 100 pregnant women without carbohydrate metabolism disorders. An assessment of hereditary, obstetric and gynecological history, as well as somatic health was carried out. Patients from the main group were subdivided into smaller groups: 1А (n = 77) – mothers whose newborns postnatally exerted adverse perinatal outcomes associated with impacting maternal hyperglycemia, and 1В (n = 73) – mothers whose newborns were born healthy. CHAID method (Chi Squared Automatic Interaction Detection) was used to create an algorithm for predicting adverse perinatal outcomes in GDМ. Аt the second stage, a single-center prospective observational non-combined cohort study was conducted to assess an effect of maternal hyperglycemia on formation of perinatal CNS lesions. Pre-labor concentration of neuron-specific enolase (NSE) was measured in the amniotic fluid of full-term fetuses in the group of pregnant women with GDM (n = 33) and in the group of pregnant women lacking carbohydrate metabolism disorders (n = 42).Results. Obesity, late reproductive age, family history of type 2 diabetes mellitus, abortions, early reproductive losses, macrosomic delivery in history are the main risk factors for GDM development. An algorithm was developed that allowed to predict a risk of newborn perinatal pathology in mother with GDM with an overall percentage of correct predictions of 68.7 ± 3.8 %. Pre-labor concentration of NSE in the amniotic fluid of full-term fetuses was elevated by 1.68 times (p = 0.006) in women with combined GDM and obesity (5.56 [3.37–6.24] ng/ml) compared to pregnant women with normal weight lacking carbohydrate metabolism disorders (3.29 [1.49–4.89] ng/ml).Conclusion. Pregnant women with obesity and type 2 diabetes mellitus familial history were featured with most prominent potential of developing perinatal complications. Rise in amniotic fluid NSE level in patients with GDМ corroborates damage of fetal CNS during antenatal period. The maximum NSE level was found in women comorbid with GDM and obesity.

show abstract

Neuron-specific enolase and brain-derived neurotrophic factor levels in umbilical cord blood in full-term newborns with intrauterine growth retardation

Cited by 7 publications

References 38 publications

The search for blood biomarkers that indicate risk of adverse neurodevelopmental outcomes in fetal growth restriction

The search for blood biomarkers that indicate risk of adverse neurodevelopmental outcomes in fetal growth restriction

Neuroprotective effect of cytoflavin in the treatment of premature newborns with hypoxic-ischemic encephalopathy

Gestational diabetes mellitus and obesity: effects on offspring

Contact Info

Product

Resources

About